Disc Medicine, Inc.
NASDAQ•IRON
CEO: Dr. Donald William Nicholson Ph.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2020-08-12
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.
Contact Information
Market Cap
$2.53B
P/E (TTM)
-11.0
17.5
Dividend Yield
--
52W High
$99.50
52W Low
$30.82
52W Range
Rank59Top 87.6%
2.2
F-Score
Modified Piotroski Analysis
Based on 5-year fundamentals
Weak • 2.2 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2021-2025
Financial Dashboard
Q4 2025 Data
Revenue
$0.00+0.00%
4-Quarter Trend
EPS
-$1.64+0.00%
4-Quarter Trend
FCF
-$43.32M+0.00%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
R&D Spending Surge Research spending reached $170.6M in 2025, marking a $74.0M increase over 2024 expenses.
Financing Activities Strong Secured $473.4M in net cash from financing activities during 2025, mainly through equity offerings.
Bitopertin NDA Submitted Submitted NDA for bitopertin accelerated approval in September 2025 for EPP and XLP indications.
Strong Cash Position Ended 2025 with $791.2M in cash, cash equivalents, and marketable securities to fund operations.
Risk Factors
Net Loss Widened Significantly Net loss reached $(212.2)M in 2025, nearly doubling from $(109.4)M reported in the prior year.
Bitopertin Regulatory Setback FDA issued a Complete Response Letter in February 2026 regarding bitopertin NDA submission.
No Product Sales Revenue Zero revenue generated from product sales; continued reliance on capital resources for future development.
High Operating Cash Burn Net cash used in operating activities totaled $(180.4)M for 2025, reflecting high pipeline investment.
Outlook
APOLLO Phase 3 Data Due Expect topline data from Phase 3 APOLLO trial in Q4 2026 to support potential traditional approval response.
DISC-0974 Data Expected Anticipate topline data for DISC-0974 in anemia of MF from RALLY-MF Phase 2 trial during 2026.
DISC-3405 Trial Updates Plan to report initial data from RESTORE-PV trial for DISC-3405 in PV during the second half of 2026.
FDA CRL Strategy Meeting Plan to request Type A meeting with FDA to review approach following the bitopertin Complete Response Letter.
Peer Comparison
Revenue (TTM)
$908.96M
$490.73M
$460.16M
Gross Margin (Latest Quarter)
95.0%
92.8%
91.0%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| IBRX | $8.24B | -22.6 | 64.3% | 175.0% |
| BLTE | $6.53B | -75.2 | -42.7% | 0.0% |
| CDTX | $5.61B | -18.6 | -60.1% | 0.4% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
N/M
Revenue Volatile
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention
Deep Research
Next earnings:May 5, 2026
EPS:-
|Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data